ABHD4
MOLECULAR TARGETabhydrolase domain containing 4
ABHD4 (abhydrolase domain containing 4) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting ABHD4
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | myricetin-3-O-galactopyranoside [Supplementary Concept] | 1.10 | 2 |
| 2 | ag490 | 1.10 | 2 |
| 3 | Chlorhexidine | 1.10 | 2 |
| 4 | Diiodotyrosine | 1.10 | 2 |
| 5 | Ethidium | 1.10 | 2 |
| 6 | Fluspirilene | 1.10 | 2 |
| 7 | Methylene Blue | 0.69 | 1 |
| 8 | Calcimycin | 0.69 | 1 |
| 9 | Cinnarizine | 0.69 | 1 |
| 10 | Demeclocycline | 0.69 | 1 |
| 11 | piceatannol | 0.69 | 1 |
About ABHD4 as a Drug Target
ABHD4 (abhydrolase domain containing 4) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented ABHD4 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
ABHD4 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.